Pelican-Cancer-Foundation-logos
Donate Now
Search
Pelican-Cancer-Foundation-logos

Dedicated to helping patients with bowel and liver cancer live well for longer

Donate Now
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Pelican OReCO
      • OReCO On-line Resources
      • OReCO Partners & Sponsors
      • Pelican OReCO Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • LARS
    • Sponsors
      • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • MERCURY 3
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

About bowel cancer treatment – TME

There is evidence in the medical literature that colorectal cancer is the most technique-dependent of all malignancies. In other words, there is greater difference in outcome in terms of cure, the number of permanent colostomies necessary and in other disabilities, including impaired sexual function, as a result of treatment technique than for any other cancer.

Precise bowel cancer surgery, particularly the Total Mesorectal Excision (TME) technique, saves more lives than any other treatment for low bowel cancer. It halves the chance of the cancer returning and minimises negative side effects such as damage to urinary and sexual function. TME has already made a life-saving, life-enhancing difference to thousands of patients all over the world.

The TME technique was developed by Pelican’s founder Professor Bill Heald at the Hampshire Hospitals NHS Foundation Trust’s Basingstoke and North Hampshire Hospital, and is recognised as the ‘gold standard’ in rectal cancer surgery worldwide. It is now adopted by surgeons across the UK, and formally adopted in Norway, Sweden, Denmark, Holland, Germany, Austria and Switzerland. The technique has become standard terminology for optimal treatment of pelvic cancer all over the world.

What is TME? TME is precise surgery – the surgeon takes his/her time to meticulously remove the part of the bowel where the tumour is sited and also includes all of the surrounding tissue (the mesorectum). It is evident from pictures of the tumour specimen after surgery when this is successfully achieved – when the surgeon has carefully followed the ‘planes of surgery’ and removed the tumour with a shiny and complete outer layer. When the specimen is irregular or damaged then the ‘margins’ may be compromised – this can lead to a recurrence of the cancer as cells might have been released into the body.

Between 2003-06, Pelican ran a National Training Programme for multi-disciplinary cancer teams across England to learn about improving treatment using TME within an effective multidisciplinary team setting. Over 2,000 clinicians attended the courses, and this programme continues with courses by Prof Heald and Mr Brendan Moran every year. In 2011, the National Cancer Action Team (NCAT) launched the Low Rectal Development Programme (LOREC) with Mr Moran as the National Clinical Lead, again run by Pelican, which focuses on the complexities of treating very low rectal cancers.

Laparoscopic surgery (minimally-invasive surgery) for bowel cancer is growing in importance and NICE guidelines now specify that suitable patients must be offered laparoscopic surgery. There are obvious advantages in not having a large scar in the abdomen and healing times are faster, but it should also be remembered that laparoscopic surgery is a tool, not a religion – and it is not always the best solution for every patient. Pelican in Basingstoke is one of the national training centres for the LAPCO programme.

The da Vinci robot is now used for TME surgery in a number of units. This is another form of minimally-invasive surgery which may give a superior view of the operating area and a very precise dissection of the ‘TME’ nerves. However the procedure takes longer and surgeons require time to become proficient.

Stay in touch

Sign up to hear from us
Donate Now

© 2023 Pelican Cancer Foundation - all rights reserved

  Registered Charity Number: 1141911 -  Privacy Policy